~~<i id='2B21328C08'><strike id='2B21328C08'><tt id='2B21328C08'><pre id='2B21328C08'></pre></tt></strike></i>~~

Home» knowledge» explore

explore

author：fashion 2025-10-02 12:18:07 Page View：4

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development.

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Beware the threat of staffing cuts at the CDC
Next article： Sports medicine is finally prioritizing gender equality

explore

BioMarin wins approval for gene therapy to treat hemophilia A

AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

People with mental disorders often marry others with same

Peoplewithmentaldisorders,includingautismandschizophrenia,tendtomarrypartnerswiththesamedisorders,as

As demand for Covid shots wanes, Moderna seeks its next success

RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

The boys, now 6, who are gene therapy’s ‘edge case’ problem

HiramSecrist(left),whohasDuchennemusculardystrophy,withhismother,KristenSecrist(center),andhisgrandm

WSS

explore

explore

leisure time

explore

The boys, now 6, who are gene therapy’s ‘edge case’ problem